Thalidomide (Thalomid, Celgene) was approved in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma.
Thalidomide (Thalomid, Celgene) was approved in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma.
FDA approved 2 higher dose formulations of valsartan/hydrochlorothiazide (Diovan HCT, Novartis) for the treatment of hypertension. The combination tablets will now be available in 320/12.5 mg and 320/25 mg doses.
FDA approved infliximab (Remicade, Centocor) to treat children aged 6 to 17 years with active Crohn's disease.
FDA and EMA Accepts Applications for New Nusinersen Regimen
January 23rd 2025An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
Read More